Building 6A at Oxford Technology Park Leased to Oxford Ionics

Oxford Ionics Limited has agreed the letting of 29,661 sq. ft. across the entirety of Building 6A at Oxford Technology Park.

Oxford Ionics Limited (“Oxford Ionics”), an Oxford University spinout and pioneer in quantum computing has agreed the letting of 29,661 sq. ft. across the entirety of Building 6A at Oxford Technology Park (“OTP”). Oxford Ionics is an existing occupier at OTP and the new lease is more than six times its existing footprint of 4,887 sq. ft. at Building One.  

Oxford Ionics’s proprietary Electronic Qubit Control technology provides the most stable and scalable method for delivering quantum computing technology.  Its pioneering performance enables the design of better catalysts used in processes such as drug discovery, experimentation in test tubes or real-time simulation on computers. 

Building 6A is an innovative, high-tech hybrid building which provides a contemporary office style frontage with flexible internal space allowing the office, R&D laboratory and production content of buildings to vary from 25% to 50% to suit a range occupier requirements. It is targeting a BREEAM Excellent certification.

Ian Harris, Director of Asset Management of Life Science REIT said:

Oxford Ionics is a great example of how OTP can accommodate fast-growing life sciences businesses by providing specialist space to meet their needs as they evolve.  At OTP, we are delivering units covering the whole spectrum: from small, more flexible and affordable space to larger hybrid buildings and plug and play lab space all in close proximity to the academic and research institutions in and around Oxford University.” 

Chris Ballance, CEO and Co-Founder of Oxford Ionics said:

“We’re very excited to take this new space at Oxford Technology Park, which will be our new HQ and the centre of our Quantum Computing as a Service offering. With the capacity to accommodate 20 of our advanced quantum systems, it will also provide space for our world-class team to grow to 150 people.”

Existing occupiers at the park include The Native Antigen Company, a developer and manufacturer of antigens and antibodies, and Oxford Gene Technology, a provider of clinical research and diagnostic solutions.

Picture of John Doe

John Doe

Lorem ipsum dolor sit amet consectetur adipiscing elit dolor

Don’t Stop Here

More To Explore

Infleqtion lease completes at OTP. First letting of...
Published on
OTP unveils a new name for its prominent...
Published on
OTP is proud to announce ConserV Bioscience as...
Published on
As proud sponsors of the CBAs 2024 Innovation...
Published on
OTP hosts keynote event, which brought together leading...
Published on
OTP, in partnership with occupier OGT, is proud...
Published on